Articles tagged "Induction therapy"

2020 American Transplant Congress
The Challenge of Selecting an Induction Agent: A Dual Regimen for Medically High-Risk Kidney Recipients
R. Craig-Schapiro, B. Magaoay, R. Grover, S. Sultan, M. Aull, S. Kapur
Weill Cornell Medical Center, New York, NY
*Purpose: Complications of the commonly used lymphocyte-depleting induction agent, rabbit anti-thymocyte globulin (rATG),include cardiorespiratory dysfunction with hypotension, tachycardia, myocardial infarction, and pulmonary edema. The choice…
2020 American Transplant Congress
Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients
J. Ahn¹, S. Bae¹, K. Lentine², M. Schnitzler², G. Hess³, D. Segev¹, M. McAdams-DeMarco¹
¹Johns Hopkins University, Baltimore, MD, ²Saint Louis University, St. Louis, MO, ³Drexel University, Philadelphia, PA
*Purpose: Kidney transplantation (KT) has been growing treatment option for older end-stage renal disease patients. Although lymphocyte-depleting agents are considered to be superior than interleukin-2…
2020 American Transplant Congress
Comparison of Clinical Outcomes of Induction Regimens in Patients Undergoing Liver Transplantation for Acute Liver Failure
C. M. Anugwom¹, J. Parekh², C. Hwang³, M. MacConmara³, W. M. Lee⁴, T. M. Leventhal¹
¹Gastroenterology, Hepatology and Nutrition, University of Minnesota Medical Center, Minneapolis, MN, ²Department of Surgery, University of California, San Diego, San Diego, CA, ³Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
*Purpose: Spontaneous survival rates in acute liver failure (ALF) are vastly improved by liver transplantation (LT). However, the value of induction agents beyond steroids continues…
2020 American Transplant Congress
Anti-T Lymphocyte Immunoglobulins versus Basiliximab in Highly Sensitized Kidney-Transplant Patients without Preformed DSAs: The Satir Study
N. Kamar¹, L. Couzi², L. Albano³, A. Durrbach⁴, V. Pernin⁵, L. Esposito¹, M. Lequintrec⁵, P. Merville², A. Del Bello¹
¹Toulouse University Hospital, Toulouse, France, ²Bordeaux University Hospital, Bordeaux, France, ³Nice University Hospital, Nice, France, ⁴Henri Mondor University Hospital, Paris, France, ⁵Montpellier University Hospital, Montpellier, France
*Purpose: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly…
2020 American Transplant Congress
Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy
R. Michael, B. Mierzejewska, D. Bekbolsynov, J. Ortiz, O. Ekwenna, S. Stepkowski
University of Toledo, Toledo, OH
*Purpose: The induction therapy is currently used in the majority of kidney transplant recipients, regardless of their level of donor/recipient compatibility. We examined whether lower…
2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
J. P. Knorr, C. Kallis, D. A. Portley, A. Jeyarajasingam, P. W. Lai, G. Bradauskaite, K. Khanmoradi
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…
2020 American Transplant Congress
Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients
H. Sasaki¹, T. Tanabe¹, H. Higuchi¹, T. Tsujimoto², H. Harada¹
¹Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, ²Pharmacy, Sapporo City General Hospital, Sapporo, Japan
*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…
2020 American Transplant Congress
Pediatric Primary Kidney Transplant Recipients Outcomes by Immunosuppression Induction Received in the United States
S. M. Riad¹, S. Jackson², A. Matas³, S. Chinnakotla³, P. Verghese⁴
¹University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN, ⁴Pediatrics, University of Minnesota, Minneapolis, MN
*Purpose: Induction immunosuppression types for pediatric transplant recipients vary widely by transplant centers. We sought to study the impact of different induction types on recipients…
2020 American Transplant Congress
Basiliximab vs Antithymocyte Globulin Induction with Early Steroid Withdrawal in Kidney Transplant Recipients: Early Rejection Outcomes
A. Szczepanik¹, C. Burrelli¹, A. Bixby¹, K. Yadav², K. Chavin²
¹Pharmacy, University Hospital Cleveland Medical Center, Cleveland, OH, ²Surgery, University Hospital Cleveland Medical Center, Cleveland, OH
*Purpose: Steroid withdrawal within the first month of kidney transplant (KT) remains controversial and has demonstrated a higher risk of acute rejection. The impact of…
2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
R. M. Hofmann¹, J. Combs², K. J. Schmidt³, T. Dyckman⁴
¹Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, ²Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, ³Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, ⁴Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…

« Previous Page
1
…
4
5
6
7
8
…
31
Next Page »